Ascendis Pharma A/S (ASND) Releases Quarterly Earnings Results
Ascendis Pharma A/S (NASDAQ:ASND) announced its quarterly earnings data on Wednesday. The company reported ($0.80) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.71) by $0.09. Ascendis Pharma A/S had a negative return on equity of 47.61% and a negative net margin of 818.32%.
Ascendis Pharma A/S (NASDAQ:ASND) opened at 20.53 on Thursday. Ascendis Pharma A/S has a 52 week low of $11.92 and a 52 week high of $21.79. The stock has a 50 day moving average of $19.75 and a 200 day moving average of $16.75. The company’s market cap is $647.21 billion.
Hedge funds have recently made changes to their positions in the stock. Baker BROS. Advisors LP acquired a new stake in shares of Ascendis Pharma A/S during the third quarter valued at approximately $14,985,000. RA Capital Management LLC boosted its stake in shares of Ascendis Pharma A/S by 7.9% in the third quarter. RA Capital Management LLC now owns 3,681,491 shares of the company’s stock valued at $73,998,000 after buying an additional 268,634 shares during the last quarter. Finally, Sphera Funds Management LTD. boosted its stake in shares of Ascendis Pharma A/S by 0.6% in the third quarter. Sphera Funds Management LTD. now owns 263,500 shares of the company’s stock valued at $5,296,000 after buying an additional 1,700 shares during the last quarter. Institutional investors and hedge funds own 44.40% of the company’s stock.
A number of equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating and set a $23.00 price objective on the stock in a report on Monday. Wedbush restated an “outperform” rating and issued a $31.00 price objective on shares of Ascendis Pharma A/S in a report on Thursday, October 20th. TheStreet upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Tuesday, September 6th. Finally, Leerink Swann reiterated a “buy” rating on shares of Ascendis Pharma A/S in a research note on Friday, September 2nd.
WARNING: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this piece of content can be viewed at http://www.dailypolitical.com/2016/12/01/ascendis-pharma-as-asnd-releases-quarterly-earnings-results.html.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.